PWM
KRYS icon

Parkworth Wealth Management’s Krystal Biotech KRYS Stock Holding History

Parkworth Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$275 Buy
+2
New +$294 ﹤0.01% 825

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Parkworth Wealth Management's KRYS Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Krystal Biotech (KRYS) in Q2 2025: 2 shares worth $275. The stake represents ﹤0.01% of the portfolio and ranks #825 among its holdings.

275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of Krystal Biotech worth $275 as of Q2 2025.
  • Krystal Biotech was a new Parkworth Wealth Management position in Q2 2025.
  • Krystal Biotech made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #825 holding.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.